Linked Life Data

17329198

Source:http://linkedlifedata.com/resource/pubmed/id/17329198

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2007-3-1
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1470-2045
pubmed:author
pubmed:issnType
Print
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
273-4
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL.
pubmed:affiliation
Institute of Haematology and Medical Oncology L. e A. Seràgnoli, University of Bologna, Italy. simona.soverini@tin.it
pubmed:publicationType
Journal Article, Case Reports, Research Support, Non-U.S. Gov't